Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
NCT01925612 · Seagen Inc. · PHASE2 · terminated · last registry update 2018-06-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision based on portfolio prioritization and changing treatment landscape in frontline DLBCL” | – | Registry record, Seagen Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-06-13Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT03984448)
- 2019-05-22Phase 3 first posted: Children's Oncology Group, Blinatumomab + Calaspargase Pegol (NCT03959085)
- 2019-04-23Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Enfortumab Vedotin (NCT03924895)
- 2019-04-16Phase 3 first posted: National Cancer Institute (NCI), Asparaginase Erwinia chrysanthemi + Blinatumomab (NCT03914625)
- 2019-04-09Phase 3 first posted: National Cancer Institute (NCI), Brentuximab Vedotin + Dacarbazine (NCT03907488)
- 2019-03-12Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Selumetinib Sulfate (NCT03871257)
- 2019-01-30Results posted on the registry: St. Jude Children's Research Hospital, Induction Chemotherapy + Low-Risk Therapy (NCT00602667)
- 2018-11-07Phase 3 first posted: Daiichi Sankyo, Trastuzumab deruxtecan (DS-8201a) + Capecitabine (NCT03734029)
- 2018-05-23Phase 3 first posted: Children's Oncology Group, Carboplatin + Cisplatin (NCT03533582)
- 2018-03-07Phase 3 first posted: Hoffmann-La Roche, Alectnib + Cisplatin (NCT03456076)
- 2018-02-27Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Carboplatin (NCT00977574)
- 2018-01-04Phase 3 first posted: Janssen Research & Development, LLC, Erdafitinib + Vinflunine (NCT03390504)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision